Reduced Efficacy

Drug concentration at desired location is limited by low percentage that reaches the target and/or potential side effects and complications in other parts of the eye that preclude higher doses.

Reduced Access

Invasive surgical approaches must be performed in an operating room which increases cost, reduces access, and delays treatment (with potentially irreversible consequences).

Patient Burden

Negative effects of poor outcomes and exposure to difficult surgical interventions with awkward recovery protocols and potential long-term consequences (i.e. cataract formation).

Dragonfleye has created a minimally invasive device for targeted delivery of fluids to the suprachoroidal and subretinal spaces, usable in an office setting

• Novel, patent-pending device designed to perform a broad range of ophthalmic procedures outside the operating room
• • Side-firing configuration to access a wider range of locations around the eye, including more posterior targets, with a fine needle extending from the inner face
  • Integrated guidelight to ensure correct positioning
  • High precision controls to advance the needle through the sclera and deliver the treatment fluid directly to the target location
  • Motorized injection for accurate volume control and handling stability with all fluid viscosities
• Less invasive methods minimize procedural complexity, which could reduce the risk of complications, recovery time and healthcare costs
• More direct access to the treatment area could result in better patient outcomes
• The device could be used to perform a broad range of ophthalmic procedures that require access to the posterior of the eye including suprachoroidal viscopexy^TM (SCVEXY^TM) for the treatment of retinal detachment